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Abstract
 
The pre-T cell receptor (TCR), which consists of a TCR-
 
b
 
 chain paired with pre–TCR-
 
a
 
(pT
 
a
 
) and associated with CD3/
 
z 
 
components, is a critical regulator of T cell development.
For unknown reasons, extremely low pre-TCR levels reach the plasma membrane of pre-T
cells. By transfecting chimeric TCR-
 
a
 
–pT
 
a
 
 proteins into pre-T and mature T cell lines, we
show here that the low surface expression of the human pre-TCR is pT
 
a
 
 chain dependent.
Particularly, the cytoplasmic domain of pT
 
a
 
 is sufficient to reduce surface expression of a con-
ventional TCR-
 
a
 
/
 
b 
 
to pre-TCR expression levels. Such reduced expression cannot be attrib-
uted to qualitative differences in the biochemical composition of the CD3/
 
z
 
 modules associ-
ated with pre-TCR and TCR surface complexes. Rather, evidence is provided that the pT
 
a
 
cytoplasmic tail also causes a reduced surface expression of individual membrane molecules
such as CD25 and CD4, which are shown to be retained in the endoplasmic reticulum (ER).
Native pT
 
a
 
 is also observed to be predominantly ER localized. Finally, sequential truncations
along the pT
 
a
 
 cytoplasmic domain revealed that removal of the COOH-terminal 48 residues
is sufficient to release a CD4-pT
 
a
 
 chimera from ER retention, and to restore native CD4 sur-
face expression levels. As such a truncation in pT
 
a
 
 also correlates with enhanced pre-TCR ex-
pression, the observed pT
 
a
 
 ER retention function may contribute to the regulation of surface
pre-TCR expression on pre-T cells.
 
Key words: human pre–T cell receptor • pT
 
a
 
 cytoplasmic tail • surface expression • 
endoplasmic reticulum retention • CD3 complex
 
Introduction
 
Development of mature 
 
a
 
/
 
b
 
 T cells inside the thymus is
controlled at two distinct check-points by the sequential ex-
pression of the pre-TCR and the mature TCR-
 
a
 
/
 
b
 
 (1–3).
Early in T cell development, pre-T cells that succeed in pro-
ductive TCR-
 
b
 
 gene rearrangements express a functional
TCR-
 
b
 
 chain which pairs with the invariant pre–TCR-
 
a
 
(pT
 
a
 
)
 
1
 
 chain and associates with CD3 components to form
the pre-TCR (4–8). Signaling through this pre-TCR com-
plex triggers a process, known as TCR-
 
b
 
 selection, which
 
induces the cellular expansion and maturation of CD4
 
2
 
CD8
 
2
 
 double negative (DN) pre-T cells into CD4
 
1
 
CD8
 
1
 
double-positive (DP) thymocytes (2, 3, 9–11), and results
in the induction of a high rate of TCR-
 
a
 
 gene rearrange-
ments (12). On productive TCR-
 
a
 
 gene rearrangements
and substitution of pT
 
a
 
 by TCR-
 
a
 
, the TCR-
 
a
 
/
 
b
 
 is ex-
pressed associated with CD3, and DP thymocytes can un-
dergo a second step of selection, known as TCR-
 
a
 
/
 
b 
 
se-
lection, during which thymocytes are rescued from
programmed cell death and induced to differentiate into
conventional single positive (SP) thymocytes, upon binding
to self-peptide–MHC complexes expressed on thymic stro-
mal cells (3).
In contrast to TCR-
 
a
 
/
 
b
 
 selection, current data support
the view that TCR-
 
b
 
 selection is independent of binding
to an extracellular (EC) ligand (13, 14) and no evidence for
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Abbreviations used in this paper: 
 
aa, amino acid(s); BCR, B cell receptor;
Cyto, cytoplasmic; DN, double negative; DP, double positive; EC, extra-
cellular; EGFP, enhanced green fluorescent protein; endo-H, endogly-
cosidase H; ER, endoplasmic reticulum; PDI, protein disulfide isomerase;
 
pT
 
a
 
, pre–TCR-
 
a
 
; SP, single positive; TM, transmembrane. 
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the existence of such a ligand has so far been provided.
However, exit from the endoplasmic reticulum (ER) and
expression at the cell surface is mandatory for the pre-TCR
complex to exert its function (15), although rules control-
ling the assembly and intracellular transport of pre-TCR
and TCR complexes may differ markedly, as the pre-TCR
is expressed only transiently during thymocyte develop-
ment, and at extremely low levels, 
 
z
 
50–100-fold lower
than those of the TCR-
 
a
 
/
 
b
 
 on mature T cells (1, 13, 16).
The inefficient expression of pre-TCR complexes on
pre-T cells is reminiscent of the inefficient expression of
the pre–B cell receptor (BCR) on pre-B cells (1, 17), and
might be related to the particular signaling function of pre-
TCR/BCR complexes during lymphoid development.
The question is, therefore, whether such differences in sur-
face expression levels are determined by specific structural
properties of the receptors or are intrinsic to the particular
developmental stage at which the receptors are expressed.
Although the precise biochemical composition of the
pre-TCR has remained elusive until recently, evidence has
now been provided that, in the mouse, it has the same sub-
unit composition as does the TCR-
 
a
 
/
 
b
 
 complex, differing
only in that the TCR-
 
a
 
 subunit has been replaced by pT
 
a
 
and that 
 
z
 
 association has been significantly weakened rela-
tive to its association with the mature TCR-
 
a
 
/
 
b
 
 (4, 7, 8,
18). Because 
 
z
 
 is required for efficient surface expression of
the other subunits of the mature TCR-
 
a
 
/
 
b
 
 including the
CD3 molecules (19–24), its weak biochemical association
with the pre-TCR could well result in a decreased stability
of the receptor complex at the cell surface. An alternative
possibility is that, as reported for the pre-BCR, surface pre-
TCR expression is controlled by a retention mechanism
that is not selective for the pre-TCR, but is inherent to the
pre-T cell stage (1, 17). In this study, we have examined this
issue by performing transfections of human chimeric TCR-
 
a
 
–pT
 
a
 
 molecules comprising distinct domains of TCR-
 
a
 
and pT
 
a
 
 into either pre-T or mature T cell lines, and pro-
vide evidence that low surface expression of the human pre-
TCR is intrinsic to the pT
 
a
 
 chain. Particularly, our results
show that the cytoplasmic (Cyto) domain of pT
 
a
 
 is suffi-
cient to promote retention in the ER and to reduce surface
expression levels of individual transmembrane (TM) pro-
teins. The possibility that the pT
 
a
 
 Cyto tail functions as an
ER retention signal that contributes to the regulation of
pre-TCR expression levels on pre-T cells is discussed.
 
Materials and Methods
 
Isolation of Thymocyte Subsets.
 
Postnatal thymocytes isolated
from thymus samples removed during corrective cardiac surgery
of patients aged 1 mo to 3 yr were fractionated by centrifugation
on Percoll (Amersham Pharmacia Biotech) density gradients as
described (25). pre-TCR/CD3
 
low
 
 pre-T cells were isolated from
the large-sized cell fraction by immunomagnetic sorting (Dynal)
as described (16).
 
Flow Cytometry.
 
PE-labeled anti-CD3 (Leu-4-PE), biotin-
conjugated anti-CD25 (7D4), and Cy5-PE-labeled anti-CD4
mAbs were obtained from Becton Dickinson, BD PharMingen,
and Caltag Laboratories, respectively. The BMA031 mAb, raised
against a monomorphic determinant of TCR-
 
a
 
/
 
b
 
 (26) was pro-
vided by Dr. R. Kurrle (Behringwerke AG, Marburg, Germany),
and the 6D6 mAb, against the human V
 
a
 
12.1
 
 TCR-
 
a
 
 domain
(27), was the gift of Dr. M. Brenner (Brigham and Women’s
Hospital, Boston, MA). Surface expression of the human pT
 
a
 
chain was determined by staining with a rabbit antiserum (ED-1)
raised against a synthetic peptide present in the pT
 
a
 
 EC domain
(16). PE-labeled streptavidin and goat anti–mouse fluorescein-,
PE-, or PE-Cy5–coupled F(ab
 
9
 
)
 
2
 
 Igs were purchased from Caltag
Laboratories. Stained cells were analyzed in a flow cytometer
(EPICS XL; Coulter Corp.) as described (25). For flow cytome-
try, COS cells were removed from culture 48 h after transfection
with PBS containing 0.02% EDTA.
 
Generation of cDNA Constructs.
 
Full-length cDNAs encoding
the human pT
 
a 
 
and the AV12S1 TCR 
 
a
 
 chain, respectively,
were cloned into the BamHI site of the pcDNA3 plasmid vector
(Invitrogen), as described previously (16). TCR-
 
a
 
–pT
 
a
 
 chimeric
constructs (see Fig. 2 A) comprising the V
 
a
 
12.1 
 
and J
 
a
 
 domains of
the AV12S1 TCR 
 
a
 
 chain fused to pT
 
a
 
 cDNA lacking the
leader sequence (
 
a
 
I), or encoding a AV12S1 TCR 
 
a
 
 chain in
which either both the TM and Cyto domains (
 
a
 
II) or exclusively
the Cyto domain (
 
a
 
III) of TCR-
 
a
 
 have been replaced with ho-
mologous domains from pT
 
a
 
, were generated by PCR using
TCR-
 
a
 
 and pT
 
a
 
 cDNAs as templates, and specific oligonucle-
otides. The sense 5
 
9
 
-ATG GAT CCT CTA GAT GAT TTT
TGC CAG CCT GTT G-3
 
9
 
 primer (with a BamHI site), corre-
sponding to the NH
 
2
 
-terminal region of the AV12S1 TCR 
 
a
 
chain (16), was used in combination with three distinct antisense
primers: 5
 
9
 
-CCC GGA TCC TGG TGC CTG TTC CTG
TTC-3
 
9
 
 (with a BamHI site), 5
 
9
 
-CGG AAT TCG GTT TTG
AAA GTT TAG GTT CG-3
 
9
 
 (with an EcoRI site), or 5
 
9
 
-CGG
AAT TCC CAG CGT CAT GAG CAG ATT AAA-3
 
9
 
 (with an
EcoRI site), which correspond to the COOH-terminal region of
either the J
 
a
 
, the EC, or the TM domains of the AV12S1 TCR
 
a
 
 chain, respectively. PCR products were either BamHI or
BamHI/EcoRI digested, and ligated into pcDNA3 plasmid con-
taining, respectively, a BamHI/XhoI PCR fragment coding for
pT
 
a lacking the leader sequence, an EcoRI/XhoI PCR fragment
encoding both the TM and Cyto pTa domains, or an EcoRI/
XhoI PCR fragment encoding the Cyto tail of pTa. Such pTa
PCR products were amplified from pTa cDNA with the anti-
sense 59-CCG CTA ACG AGT CAG GCA GCA GCT CCA
GCC TGC AG-39 primer, corresponding to the COOH-termi-
nal region of the pTa Cyto domain, and containing an XhoI site,
in combination with the sense primers 59-CCC-GGA TCC
ATA TGC TAC CCA CAG GTG TGG GC-39, including a
BamHI site, or 59-CGG AAT TCT GTG GCT GGG GGT
CCT GCG-39, with an EcoRI site, or 59-CGG AAT TCT TAC
CTG CAG CTG CCT GTG CG-39, including an EcoRI site,
respectively.
Full-length cDNAs encoding murine CD25 (provided by Dr.
L.R. Borlado, Centro Nacional de Biotecnología, Madrid, Spain)
or human CD4 (28) were subcloned into the BamHI site of
pcDNA3. CD25-pTa and CD4-pTa chimeric constructs, com-
prising the complete EC and TM domains of CD25 or CD4
fused to the pTa Cyto tail, were generated by PCR amplifica-
tion. CD25 PCR products obtained with the sense 59-ATG
GAT CCA AGA TGG AGC CAC GTC TGC TG-39 primer
and the antisense 59-GCG AAT TCC CCA GGT GAG CCC
GCT CAG G-39 primer were digested with BamHI/EcoRI, and
CD4 PCR products obtained with the sense 59-AGA GAG AGA
GAG AAG CTT TCG GCA AGG CCA CAA TGA AC-391047 Carrasco et al.
primer and the antisense 59-GCG AAT TCC GAA GAA GAT
GCC TAG CCC AAT G-39 primer were digested with HindIII/
EcoRI. Digested PCR products were independently ligated into
pcDNA3 containing the EcoRI/XhoI PCR fragment encoding
the pTa Cyto tail described above. Truncated CD4-pTa chime-
ras lacking either the COOH-terminal 22 (CD4-pTat22) or 48
(CD4-pTat48) residues of the pTa Cyto tail were generated es-
sentially as described for CD4-pTa chimeric constructs, except
that pTa PCR was performed with the sense primer correspond-
ing to the NH2-terminal region of the pTa Cyto domain de-
scribed above, in combination with the antisense 59-AGA GAG
AGA GAG GAT ATC TCA AGC CCT GAG GCG AGA TCT
TG-39 or 59-AGA GAG AGA GAG GAT ATC TCA TAC
TGG GCT CCC GGG CTT C-39 primers, for CD4-pTat22
and CD4-pTat48, respectively. EcoRI/EcoRV-digested PCR
products were then ligated into pcDNA3 containing the Hind-
III/EcoRI-digested CD4 product described above. These anti-
sense primers were independently used with a previously de-
scribed sense primer (16) corresponding to the NH2-terminal
pTa region to generate truncated pTa proteins with identical de-
letions in the Cyto tail (pTat22 and pTat48). EcoRI/EcoRV-
digested products were independently ligated into pcDNA3.
Both cDNAs as well as full-length pTa and TCR-a cDNAs (16)
were subsequently subcloned into the bicistronic expression vec-
tor pCIGFP. To construct the pCIGFP plasmid, a NotI cassette
containing an internal ribosomal entry site (IRES) sequence fol-
lowed by the enhanced green fluorescent protein (EGFP) cDNA
was transferred from the pLZRS retroviral vector (29), provided
by Dr. H. Spits (Netherlands Cancer Institute, Amsterdam, The
Netherlands), into the NotI site in the pcDNA3 vector. Tailless
pTa cDNA was generated by amplification with the sense primer
described previously (16) in combination with the 59-GGG GGA
TCC TAC AGG AGC AGG TCA AAC AG-39 antisense
primer, BamHI digested, and ligated into the pCIGFP bicistronic
plasmid. Each construct was sequenced directly in pcDNA3. The
pTa-EGFP construct has been described previously (16).
Cell Lines and Transfection. The TCR-a–deficient JR3.11
mutant, derived from the mature human T cell line Jurkat (30;
provided by Dr. B. Rubin, Centre National de la Recherche Sci-
entifique, Toulouse, France), the human pre-T cell line SUP-T1
(31), and the murine lymphoid cell line BW, were grown in
RPMI 1640 (Biowhittaker) supplemented with 10% FCS
(GIBCO BRL). COS cells were grown in DMEM (Biowhit-
taker) supplemented with 5% FCS (GIBCO BRL). Transfections
were carried out by electroporation as described (16).
Generation of Polyclonal Anti–Human pTa Abs. A rabbit anti-
serum (CT-1) was generated against a synthetic peptide corre-
sponding to the human pTa sequence 200–212 present in the
Cyto domain (25), essentially as described previously for the ED-1
antiserum (16). The specificity of the CT-1 antiserum was assayed
by immunofluorescence microscopy of COS cells transfected
with a pTa cDNA tagged with a c-myc epitope recognized by
the specific 9E10 mAb (unpublished results).
Cell Surface Radioiodination, Immunoprecipitation, and N-Gly-
cosidase F Digestion. Cells (107) were washed with PBS, resus-
pended in 0.5 ml of PBS containing 0.5 mg/ml of sulfo-
succinimidyl-3-(4-hydroxyphenyl) propionate (SHPP)
(Boltont-Hunter reagent; Pierce Chemical Co.), and incubated
on ice for 30 min. The reaction was stopped by diluting the cells
with 10 ml of 10 mM l-lysine (Sigma-Aldrich) in PBS. Cells
were centrifuged, resuspended in 150 ml of PBS, and 125I-labeled
by the lactoperoxidase method. In brief, 1 mCi Na125I (Amer-
sham Pharmacia Biotech) and 30 ml of 140 IU/ml lactoperoxi-
dase (Sigma-Aldrich) solution were added to the cells, and 10 ml
aliquots of 0.06% H2O2 solution were then added three times, at
7-min intervals. The reaction was stopped by adding 20 mM KI
(Sigma-Aldrich) and 1 mM l-tyrosine (Sigma-Aldrich) in PBS.
Subsequently, the cells were lysed in 1% Brij 96–containing
(Sigma-Aldrich) lysis buffer (10 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 10 mM iodoacetamide, 1 mM PMSF, and 1 mg/ml each
of leupeptin, pepstatin, and aprotinin) and centrifuged for 14,000
rpm for 30 min at 48C. The supernatants were precleared three
times with normal mouse serum (NMS) Igs coupled to protein
A/G-Sepharose beads (Amersham Pharmacia Biotech) and sub-
jected to immunoprecipitation with the indicated Abs coupled to
protein A/G-Sepharose beads. The following Abs were used: the
6D6 anti–human TCR Va12.1 mAb (27); the UCHT1 anti–human
CD3e mAb (32); the 448 anti–human TCR-z rabbit antiserum,
generously provided by Dr. B. Alarcón (Centro de Biología Mo-
lecular Severo Ochoa, Madrid, Spain); and the CT-1, anti–human
pTa rabbit antiserum, generated in this study. The immunopre-
cipitates were washed five times with 1% Brij 96–containing lysis
buffer and, when indicated, digested overnight with N-glycosi-
dase F (N-Gly; 0.2 U/sample; Roche Diagnostics). For analysis,
the immunoprecipitates were separated by SDS-12% PAGE un-
der nonreducing conditions or, alternatively, by two-dimensional
gels using SDS-10% polyacrilamide tube gels in the first dimen-
sion (nonreduced), which were subsequently resolved by SDS-
12% PAGE in the second dimension (reduced).
Immunofluorescence and Confocal Microscopy. 48 h after transfec-
tion, COS cells were fixed with 2% paraformaldehyde, permeabi-
lized with 0.1% saponin in PBS containing 1% BSA, and stained
either with the PC61 fluorescein-labeled anti–mouse CD25 mAb
(BD PharMingen), or with the HP2.6 anti–human CD4 mAb
(provided by Dr. F. Sánchez-Madrid, Hospital de la Princesa,
Madrid, Spain), followed by goat anti–mouse fluorescein-coupled
F(ab9)2 Igs (Caltag Laboratories). The coverslips were viewed us-
ing a Radiance 2000 confocal microscope (Bio-Rad Laboratories).
For confocal analysis, pTa-GFP SUP-T1 stable transfectants
were adhered to Poly L-Lys (Sigma-Aldrich) precoated coverslips
(5 3 105 cells/coverslip). Coverslips were then washed in PBS,
fixed with 2% paraformaldehyde in PBS for 10 min, permeabi-
lized for 5 min with 0.05% Triton X-100 (Sigma-Aldrich), and
blocked with 2% BSA/PBS. Cells were then consecutively
stained with the anti–TCR-b bF1 mAb (provided by Dr. M.
Brenner) in combination with Cy5-conjugated goat anti–mouse
Igs (Jackson ImmunoResearch Laboratories), and with a rabbit
antiserum against the ER resident protein PDI (protein disulfide
isomerase; StressGen Biotechnologies) plus Cy3-conjugated goat
anti–rabbit Igs (Jackson ImmunoResearch Laboratories). Confo-
cal microscopy was performed on a Radiance 2000 (Bio-Rad
Laboratories) system coupled to an Axiovert S100TV inverted
microscope (ZEISS). Fluorescein and EGFP, Cy3, and Cy5 fluo-
rescence were detected using bandpass filter HQ515/30, longpass
filter HQ600/50, and longpass filter HQ660LP, respectively.
Metabolic Labeling, Immunoprecipitation, and Endoglycosidase H
Treatment. 48 h after transfection, COS cells were rinsed in PBS
twice and incubated for 30 min in DMEM without l-cysteine
and  l-methionine. Then, 500 mCi [35S]methionine/cysteine
(Amersham Pharmacia Biotech) were added, and cells were
pulsed for 30 min followed by chase periods, in the presence of
DMEM supplemented with 10% FCS. Finally, the cells were
washed in PBS, lysed in 1% Triton X-100 (Sigma-Aldrich) lysis
buffer, and immunoprecipitated either with the PC61 anti–
mouse CD25 mAb (BD PharMingen), with the CT-1 rabbit an-
tiserum against the human pTa tail, or with the HP2.6 anti–1048 An ER Retention Function for the pre–TCR-a Cytoplasmic Tail
human CD4 mAb. The immunoprecipitates were digested
overnight with endoglycosidase H (endo-H; Roche) or left undi-
gested, and resolved by SDS-12% PAGE under reducing condi-
tions. Signal intensity was quantitated by densitometry (Bio-
imaging BAS 1500; Fujifilm).
Results
Low Surface Pre-TCR Expression Is pTa Chain Depen-
dent. As shown by flow cytometry using an anti-pTa an-
tiserum and an anti-CD3 mAb (16), the human pre-TCR
is expressed on the surface of primary pre-T cells at very
low levels, compared with expression levels of the mature
TCR-a/b on SP thymocytes (Fig. 1 A) or peripheral T
cells (not shown). Low pre-TCR expression such as that
found on primary pre-T cells was detected also on a pre-T
cell line, SUP-T1 (Fig. 1 B), which expresses TCR-b and
pTa chains but lacks TCR-a (31). It is thus possible that,
as proposed for the pre-BCR (1, 17), the pre-TCR is ex-
pressed at low surface levels due to regulatory mechanisms
that operate selectively at early developmental stages. In
that case, one would expect that only limited amounts of a
conventional mature TCR-a/b could reach the plasma
membrane of pre-T cells. In contrast, we found that the in-
troduction of a conventional TCR a chain (Va12.1) into
SUP-T1 pre-T cells (awt) resulted in a reproducible in-
crease (z15-fold) in surface expression levels of CD3, pre-
sumably through the formation of heterodimers composed
of the transfected TCR-a paired with the endogenous
TCR-b and associated with CD3. Accordingly, CD3 was
found coexpressed in stoichiometric amounts with the
TCR-a/b on stable SUP-T1 awt transfectants (Fig. 1 B).
It remains possible that one component of the low level
pre-TCR expression could be limiting amounts of the en-
dogenous pTa chain, whereas increased TCR-a/b surface
density on awt transfectants could be the result of TCR-a
overexpression. To rule out that possibility, a pTa–GFP
chimeric construct (16) was introduced into SUP-T1 cells,
and surface expression of CD3 was analyzed by flow cy-
tometry on stable pTa–GFP transfectants traced by their
GFP expression. As shown in Fig. 1 C, GFP1 cells dis-
played surface CD3 levels that were indistinguishable from
those observed on nontransfected SUP-T1 cells, but still
15-fold lower than CD3 levels on awt transfectants. More-
over, surface CD3 was coexpressed with the pTa–GFP
chimeric protein (Fig. 1 B) and with the endogenous
TCR-b chain (16) in stoichiometric amounts, indicating
that pTa overexpression does not alleviate endogenous
pre-TCR components from the regulatory mechanisms
that control their limited expression on the surface of pre-T
cells. We thus concluded that pTa amounts are not rate
limiting for the assembly and expression of the pre-TCR
on the surface of SUP-T1 pre-T cells.
Reciprocal experiments aimed at analyzing surface pre-
TCR expression levels on mature T cells were then per-
formed by introduction of pTa or TCR-a into a TCR-a–
deficient mutant (JR3.11) derived from the mature T cell
line Jurkat (30). As shown in Table I, low pre-TCR and
high TCR-a/b surface expression levels, identical to those
observed on SUP-T1 pre-T cells, were consistently de-
tected on JR3.11 T cells. These data indicate that differ-
ences in surface expression levels of the pre-TCR and the
TCR are not intrinsic to the particular cell type in which
these receptors are expressed, but may be due to the pres-
ence of a pTa chain in the former and of a TCR a chain
in the latter.
The Cyto Tail of pTa Is Sufficient to Reduce Surface Expres-
sion of a Conventional TCR a Chain to pTa Expression Lev-
els. To uncover the structural properties of the pTa mol-
ecule that might account for the low surface expression of
the pre-TCR, TCR-a–pTa chimeric chains were gener-
ated as illustrated in Fig. 2 A, by replacing the Cyto, TM,
and EC Ig-like constant (C) domains of a TCR a chain
Figure 1. Flow cytometry analysis of human thymocytes and SUP-T1
transfectants. (A) Primary human pre-T cells, isolated ex vivo as described
in Materials and Methods, were analyzed by flow cytometry for surface
expression of pTa and CD3 using a rabbit anti–human pTa Ab plus a
fluorescein-conjugated second reagent and a PE-labeled anti-CD3 mAb.
Phenotypic analysis of SP thymocytes was performed on electronically
gated CD3bright large-sized thymocytes stained for surface expression of a
mature CD3-associated TCR-a/b with an anti–TCR-a/b mAb plus a
fluorescein-labeled second reagent and a PE-labeled anti-CD3 mAb. (B)
SUP-T1 pre-T lineage cells were mock transfected (SUP-T1) or trans-
fected either with a human TCR-a (Va12.1) cDNA (awt) or with a pTa-
GFP cDNA (pTa-GFP). Stable transfectants were analyzed by flow cy-
tometry for the coexpression of pTa and CD3 or TCR-a/b and CD3 as
described above. (C) Relative levels of surface CD3 expressed on mock-
transfected SUP-T1 (shaded histogram) are compared with those ex-
pressed on TCR-a (awt) transfectants (thin line) or pTa–GFP (bold line)
transfectants. Background values (dotted line) were obtained with an iso-
type-matched irrelevant PE-coupled mAb.1049 Carrasco et al.
bearing a Va12.1 domain with homologous domains from
the pTa chain. The chimeric constructs were introduced
into SUP-T1 pre-T cells, and the resulting stable transfec-
tants were assayed by flow cytometry for surface expression
of the chimeric TCRs using a mAb against their shared
Va12.1 domain. Cells stably transfected with the wild-type
TCR a chain (awt) were analyzed in parallel to control
surface expression levels of conventional TCR-a/bs. After
screening of up to 70 stable transfectants of each type, no
surface expression of the aI chimera consisting of a pTa
chain lacking the peptide leader fused to the Va12.1 and Ja
domains of TCR-a was found (Fig. 2 B). However, the aI
chimeric protein could be detected intracellularly in COS
transfectants (data not shown), thus confirming that the
TCR-a modification had not adversely affected protein
expression. Therefore, it remains possible that the aI chi-
mera does not associate properly with TCR-b, preventing
its surface expression and/or detection. Surprisingly, TCR-
a–pTa chimeras in which both the TM and Cyto domains
(aII) or exclusively the Cyto domain (aIII) of TCR-a
were replaced with the equivalent pTa domains were
found expressed at the cell surface, although at levels that
were reproducibly 10–15-fold lower than those of awt
(Fig. 2 C), but comparable to those of endogenous pTa or
transfected pTa–GFP chimeric chains (Fig. 1 C). Impor-
tantly, when the awt and the aII and aIII chimeric chains
were introduced into the TCR-a–deficient JR3.11 mature
T cell line, their relative surface expression levels were
identical to those expressed on SUP-T1 pre-T cells (Table
I). Taken together, these data provide evidence that replac-
ing the Cyto domain of TCR-a with the pTa Cyto tail is
sufficient to reduce TCR a chain surface expression (and,
hence, expression of the chimeric TCR, see below) to
conventional pTa chain expression levels, whereas the TM
domains of the TCR-a and pTa chains were equivalent
for surface expression of the TCR-a–pTa chimera.
CD3/z Components Are Physically Associated in the Wild-
type Pre-TCR as well as in the TCR-a–pTa Chimeric
TCRs. Three-color flow cytometry showed that the
wild-type TCR a chain and the aII and aIII (aI was not
studied further) chimeric proteins were expressed at the cell
surface in stoichiometric amounts with TCR-b (Vb1.1)
and CD3 (data not shown), indicating that surface expres-
sion of awt, aII, and aIII chains must be achieved by pair-
ing them with the endogenous TCR-b chain and CD3/z
components. Therefore, the cyto tail of pTa appears suffi-
cient to reduce surface expression of the chimeric TCR
complex to pre-TCR expression levels. To assess whether
Table I. Relative Levels of Surface pre-TCR, Mature TCR-a/b, 
and Chimeric TCR Expression on Stable Transfectants Derived from 
Human Pre-T Cell and Mature T Cell Lines
SUP-T1
(mean of FL 6 SD)
JR3.11
(mean of FL 6 SD)
pTa 1.2 6 0.5 1.5 6 0.7
awt 14.1 6 2.0 13.3 6 2.0
aII 1.3 6 0.4 1.4 6 0.3
aIII 2.2 6 0.5 2.4 6 0.8
TCR-a–deficient pre-T cell (SUP-T1) and mature T cell (JR3.11) lines
were stably transfected either with a wild-type TCR-a construct (awt)
or with the TCR-a–pTa aII or aIII chimeric constructs described in
Materials and Methods. SUP-T1 and JR3.11 transfectants were analyzed
by flow cytometry for the surface expression levels of the conventional
TCR-a/b and those of the chimeric TCR by staining with either a
mAb against the Va12.1 domain shared by the TCR-a and TCR-a–
pTa chains, or with an anti-CD3 mAb, respectively. Levels of surface
expression of endogenous pre-TCR on SUP-T1 pre-T cells were
compared to pre-TCR levels on pTa transfectants derived from JR3.11
mature T cells by staining with a rabbit anti–human pTa Ab (reference
16) and flow cytometry. Data are presented as the mean of fluorescence
intensity (FL) 6 SD of four to six individual transfectants.
Figure 2. The Cyto tail of pTa is sufficient to reduce levels of surface
expression of a conventional TCR a chain to pTa expression levels. (A)
Schematic representation of the three chimeric TCR-a–pTa chains (aI,
aII, and aIII), and of the wild-type TCR-a ( awt) and pTa (pTa)
chains. (B) Stable transfectants derived from SUP-T1 human pre-T cells
were selected in the presence of G-418, and analyzed by flow cytometry
for surface expression levels of the aI, aII, or aIII TCR-a–pTa chimeric
chains or the wild-type TCR a chain with an anti-Va12.1 mAb plus a PE-
labeled goat anti–mouse IgG1 (shaded histograms). Background staining
(unshaded histograms) was determined with a nonreactive mouse IgG1
mAb plus PE-coupled goat anti–mouse IgG1. Results are representative
of at least 10 different stable transfectants. (C) Mean fluorescence values 6
SD of surface expression of TCR-a (awt) and aII and aIII chimeric
chains on three distinct stable transfectants of each type. Results are repre-
sentative of 60–70 distinct transfectants of each type and summarize the
data from six experiments.1050 An ER Retention Function for the pre–TCR-a Cytoplasmic Tail
this effect could be attributed to defective TCR–CD3/z
interactions, we directly compared the biochemical com-
position of chimeric TCRs with that of conventional
TCR-a/bs, and pre-TCR complexes containing a wild-
type pTa chain. To this end, the awt, aII, and aIII stable
transfectants were surface iodinated, treated with 1% Brij
96–containing lysis buffer, and surface TCRs were immu-
noprecipitated from cell lysates with a mAb specific for
their shared Va12.1 domain. The untransfected SUP-T1
pre-T cell line was simultaneously labeled and the endoge-
nous pre-TCR complex was immunoprecipitated from cell
lysates with a rabbit antisera (CT-1) raised against a syn-
thetic peptide contained in the Cyto region of the human
pTa molecule. Specificity of the affinity-purified Ab was
confirmed previously by immunofluorescence microscopy
of COS cells transfected with a c-myc–tagged pTa chain
(data not shown). Subsequently, the immunoprecipitates
were mock treated or treated with N-Gly, in order to dis-
tinguish between CD3e and CD3d chains, and resolved by
SDS-PAGE under nonreducing conditions. As shown in
Fig. 3, a conventional TCR-a/b heterodimer of 90 kD
was coimmunoprecipitated with CD3gde from the surface
of  awt transfectants, whereas fewer CD3gde-associated
chimeric TCRs of an apparent MW of 115 kD were im-
munoprecipitated from both aII and aIII transfectants.
N-Gly treatment of the immunoprecipitated proteins re-
sulted in an increase in their electrophoretic mobility by
elimination of their glycosidic component, and revealed no
qualitative biochemical differences in the composition of
the CD3 modules associated with conventional and chi-
meric TCRs, as all g, d, and e CD3 components were re-
producibly precipitated with both heterodimers. Similarly,
CD3g, CD3d, and CD3e chains were all associated with a
pTa-containing complex of 100 kD immunoprecipitated
from the surface of untransfected SUP-T1 pre-T cells, cor-
responding to the endogenous pre-TCR. However, copre-
cipitation of z chain components either with the pre-TCR
or with the chimeric or the conventional TCR-a/bs was
not detected under these experimental conditions, likely
Figure 3. Biochemical composition of pre-TCR and chimeric TCR
complexes expressed on SUP-T1 transfectants. Surface 125I-labeled SUP-
T1 pre-T cells either mock transfected (SUP-T1) or transfected with
wild-type TCR-a (awt) or with aII and aIII TCR-a–pTa chimeric
chains were lysed in 1% Brij 96–containing buffer, and the surface recep-
tors were immunoprecipitated with an anti-Va12.1 mAb or with a rabbit
antiserum against the pTa CY domain. Immunoprecipitates (107 cell
equivalents per lane) were either digested with N-Gly (1) or left un-
treated (2), and resolved by 12% SDS-PAGE under nonreducing condi-
tions. The positions of the pTa–TCR-b, TCR-a/b, aII–TCR-b and
aIII–TCR-b heterodimers, CD3de, and CD3g chains, and deglycosyl-
ated CD3g (dg) and CD3d (dd) are indicated on the right. The migration
positions of the molecular weight standards (in kD) are indicated on the
left. *, N-deglycosylated heterodimers.
Figure 4. The z chain is physically associated to the pre-TCR as well
as to the aIII chimeric TCR. Surface iodinated SUP-T1 cells either
mock transfected (SUP-T1) or transfected with the aIII TCR-a–pTa
chimera (aIII) or with the wild-type TCR a chain were lysed in 1% Brij
96–containing buffer and surface receptors were then immunoprecipi-
tated with a rabbit anti–human z chain antiserum or with an anti-CD3e
mAb. The immunoprecipitates (IP) were resolved by two-dimensional
nonreducing (NR)/reducing (R) SDS-PAGE. The positions of the indi-
vidual pre-TCR or TCR components migrating out of the diagonal are
shown, and the relative positions of the molecular weight standards are
indicated on the right.1051 Carrasco et al.
reflecting poor z chain iodination due to its short EC do-
main (33).
To directly investigate whether the z chain was physi-
cally associated with the pre-TCR and the chimeric TCRs
as with the conventional TCR-a/bs, cell lysates from sur-
face-iodinated SUP-T1 pre-T cells and awt and aIII trans-
fectants were immunoprecipitated in parallel either with a
rabbit anti–human z chain antiserum or with an anti-CD3e
mAb, and the immunoprecipitates resolved by two-dimen-
sional nonreducing/reducing SDS-PAGE. As shown in Fig.
4, the anti-CD3e mAb coprecipitated the TCR-a/b, as
well as the aIII chimeric TCR, and the pre-TCR with
CD3gde, whereas no z chain was detected. However, the z
chain was detected as an individual protein migrating out of
the diagonal with an apparent MW of 16 kD in anti-z im-
munoprecipitates. Interestingly, in all samples the anti-z Ab
coprecipitated an heterodimeric complex together with
CD3gde, indicating that the z chain is physically associated
at the cell surface with the pre-TCR and with the aIII chi-
meric TCR, as observed with the mature TCR-a/b. Fur-
thermore, it is worth noting that the wild-type pre-TCR
was precipitated with both the anti-CD3e and anti-z Abs
not only from the untransfected SUP-T1 cells, but also
from the surface of awt and aIII SUP-T1 transfectants (Fig.
4), indicating that the conventional TCR a chain (or the
aIII chimeric chain) does not prevent surface expression of
the endogenous pre-TCR but, rather, both the pre-TCR
and the TCR-a/b can be coexpressed at the cell surface.
The Cyto Tail of pTa Functions As an ER Retention Sig-
nal. As biochemical studies provided evidence that low
surface expression of the pre-TCR and the chimeric TCRs
does not result from their impaired association with CD3/z
components (although quantitative differences can not be
ruled out), we next investigated whether the pTa Cyto tail
by itself could be directly responsible for controlling surface
expression levels of the whole receptor complex. To test
this possibility, we first analyzed the effect of the pTa Cyto
domain on the surface expression levels of individual
plasma membrane reporter proteins. Murine CD25 (IL-2
receptor a chain) is a particularly useful marker in this type
of study, because transfection of the wild-type protein re-
sults in high surface expression level, as assessed by flow cy-
tometry with an anti-CD25 mAb (Fig. 5). Interestingly, we
found that replacement of the CD25 Cyto domain with
that of pTa results in a .50-fold reduction of surface
CD25 expression on COS cells transfected with the
CD25–pTa chimera, compared with surface expression
levels of wild-type CD25. A comparable reduction of
CD25 expression was observed in SUP-T1 pre-T cells
transfected with the CD25–pTa chimera (Fig. 5). In both
cell types, the relative levels of CD25 expression were not
Figure 5. Impaired surface ex-
pression of a CD25–pTa chi-
meric protein bearing the human
pTa Cyto tail. Relative levels of
surface expression of murine
CD25 were analyzed by flow
cytometry (shaded histograms)
with a biotin-coupled anti-
CD25 mAb plus PE-coupled
streptavidin on SUP-T1 pre-T
cells or COS cells transfected
with either the wild-type murine
CD25 (CD25), a truncated
CD25 molecule lacking the cy-
toplasmic domain (CD25 tail-
less), or a chimeric protein con-
sisting of the CD25 EC and TM
domains and the pTa Cyto tail
(CD25/pTa). Mock-transfected
cells were analyzed as controls.
Background values (unshaded
histograms) were determined by
staining with a biotin-coupled
isotype-matched irrelevant mAb
plus PE-coupled streptavidin.
Figure 6. ER retention of a CD25–pTa chimeric protein bearing the
Cyto tail of human pTa. (A) COS cells were transfected with either
cDNA encoding the wild-type murine CD25 or with a CD25/pTa chi-
meric cDNA engineered to encode the CD25 EC and TM domains and
the pTa Cyto tail (CD25/pTa). 48 h after transfection, cells were fixed,
permeabilized, stained with a fluorescein-conjugated anti-CD25 mAb,
and analyzed by immunofluorescence microscopy. Original magnification:
363. (B) CD25 and CD25-pTa COS transfectants were pulse-chase la-
beled with [35S]methionine/cysteine and lysed in Triton X-100–contain-
ing lysis buffer. CD25 (top) and CD25-pTa (bottom) immunoprecipi-
tates obtained with an anti–mouse CD25 (PC.61) mAb or with a rabbit
antiserum against the human pTa tail (CT-1), respectively, were treated
with endo-H (1) or left untreated (2) and resolved by 12% SDS-PAGE
under reducing conditions. The positions of the mature (m) and imma-
ture (im) proteins is indicated on the right.1052 An ER Retention Function for the pre–TCR-a Cytoplasmic Tail
altered by deletion of the CD25 cyto tail (CD25 tailless),
confirming that impaired CD25 surface expression was in-
deed due to the presence of the pTa Cyto tail.
To assess whether the CD25–pTa chimeric protein was
retained intracellularly, COS transfectants were permeabi-
lized and examined for the intracellular distribution of
CD25 by immunofluorescence microscopy. As shown in
Fig. 6 A, transfection of wild-type CD25 resulted in a pre-
dominant localization of the protein in the Golgi apparatus,
although CD25 expression was also detected at the plasma
membrane. However, a markedly different staining pattern
showing strong perinuclear fluorescence and a tubular-
vesicular peripheral staining was observed in COS cells
transfected with the CD25–pTa chimera, which strongly
suggested an ER distribution. To confirm that the pTa tail
was in fact conferring ER residence to membrane proteins,
we next examined susceptibility to endo-H digestion of
wild-type and chimeric CD25–pTa molecules, as protein
transport out of the ER to the Golgi apparatus is marked by
acquisition of endo-H resistance (34). To this end, COS
transfectants were labeled for 30 min with [35S]methionine
and chased for various periods of time up to 8 h, and Tri-
ton X-100–solubilized molecules were then subjected to
immunoprecipitation with an anti-CD25 mAb or with an
antiserum against the pTa Cyto tail (CT-1). Mock-treated
or endo-H–treated proteins were then analyzed for their
glycosylation state by SDS-PAGE, as endo-H sensitivity
causes a marked change in the electrophoretic mobility of
CD25. As shown in Fig. 6 B (top), a significant fraction
(z40%, as quantified by densitometric analysis) of wild-
type CD25 acquired endo-H resistance after 1 h of biosyn-
thesis, and was completely converted after 4 h. The situa-
tion was markedly different for the CD25–pTa chimeras
analyzed from either anti-pTa (Fig. 6 B, bottom) or anti-
CD25 precipitates (data not shown), as none of them ac-
quire endo-H resistance, even after a 4-h chase. In contrast
to wild-type CD25, which was partly degraded after 4 h
and was hardly detectable after 8 h, up to 20% of pulsed
CD25–pTa was still recovered essentially in an immature
form after 8 h (Fig. 6 B). Therefore, the lack of maturation
of the chimeric protein does not result from their increased
degradation rate in the ER. Rather, we can conclude that a
major proportion of the CD25–pTa chimeric proteins pri-
marily reside in the ER and, therefore, cannot be processed
in the Golgi apparatus. Taken together, the biosynthetic
data in conjunction with the flow cytometry and immuno-
fluorescence microscopy analyses provide evidence that the
Cyto tail of the human pTa molecule confers ER resi-
dency to plasma membrane proteins.
The physiological relevance of these findings was further
confirmed by confocal microscopy studies aimed at analyz-
ing the intracellular distribution of the native pTa protein
in pre-T cells displaying poor surface expression of the pre-
TCR (Fig. 7). When permeabilized SUP-T1 pre-T cells
were stained with the rabbit anti-pTa Ab CT-1 in combi-
nation with fluorescein-conjugated goat anti–rabbit Igs, na-
tive pTa showed a typical intracellular staining compatible
with ER location (data not shown). An identical intracellu-
lar pattern was revealed by green fluorescence examination
of SUP-T1 pre-T cells transfected with a pTa–GFP chi-
meric protein (Fig. 7). To provide formal proof that the in-
tracellular compartment containing pTa was in fact the
ER, double-color analyses were performed in pTa–GFP
transfectants stained with a rabbit Ab recognizing the ER
resident PDI protein followed by Cy3-conjugated goat
anti–rabbit Igs. As shown in Fig. 7, GFP clearly localized to
the same intracellular region as the PDI protein in pTa–
GFP transfectants. Moreover, costaining with an anti–
TCR-b ( bF1) mAb followed by Cy5-conjugated goat
anti–mouse Igs revealed that endogenous TCR-b colocal-
Figure 7. Colocalization of pTa-GFP with the ER-resident protein PDI. SUP-T1 cells stably transfected with pTa–GFP were fixed, permeabilized,
and stained with an anti–TCR-b mAb followed by Cy5-coupled goat anti–mouse Igs, and an anti-PDI rabbit antiserum followed by Cy3-coupled goat
anti–rabbit Igs. Analysis of pTa–GFP and TCR-b intracellular localization was performed by confocal microscopy. (a) Nomarsky analysis of selected in-
dividual cells. (b) Expression pattern of the pTa–GFP chain. (c) Intracellular staining of the ER-resident protein PDI. (d) Intracellular TCR-b chain
staining. (e–g) Overlays of pTa-GFP and PDI (e), pTa–GFP and TCR-b (f), and TCR-b and PDI (g) stainings. The panels of individual cells shown are
representative of all SUP-T1 cells examined. Original magnification: 363.1053 Carrasco et al.
ized with GFP and PDI. Thus, from these experiments we
concluded that intracellular pTa and TCR-b are predomi-
nantly retained in the ER in SUP-T1 pre-T cells.
Partial Truncation of the pTa Cyto Tail Releases a CD4–
pTa Chimeric Protein from ER Retention and Restores Cell
Surface Protein Expression. Collectively, the above experi-
ments provided evidence that the Cyto domain of pTa is
directly responsible for retaining proteins in the ER. Thus,
it was reasonable to predict that deletion of the pTa tail
(and, therefore, the proposed ER retention determinants)
would result in enhanced expression of the pre-TCR com-
plex at the plasma membrane. However, the effect of the
pTa tail deletion was the opposite, as it prevented surface
pre-TCR expression. Indeed, JR3.11 cells transfected with
a tailless pTa chain failed to react with anti-CD3 mAbs
(Fig. 8 A), as well as with an anti–TCR-b (Vb8) mAb and
an anti-pTa Ab (data not shown). This unexpected dis-
crepancy could be explained if the cytoplasmic domain of
pTa contains essential structural information for the proper
assembly and/or surface expression of a CD3-associated
pre-TCR.
The failure to observe surface expression of a pre-TCR
with a complete deletion of the pTa tail prompted us to
define more precisely the location of the potential ER re-
tention signal in the pTa Cyto domain. To this end, we
examined the effect of successive truncations along the
pTa tail on the intracellular location and surface expression
levels of individual CD4–pTa chimeric proteins which
could be readily detected by staining with a mAb against
CD4. As shown in Fig. 8 B, immunofluorescence micros-
copy analyses of COS cells transfected with CD4–pTa chi-
meric constructs where the Cyto domain of human CD4
was replaced with the full pTa tail (CD4–pTa) revealed a
clear tubular-vesicular staining of the ER that was virtually
identical to that recorded for the CD25–pTa chimera (Fig.
6 A), and correlated with low surface CD4 expression on
both COS (data not shown) and BW cells (Fig. 8 B). No
loss of the CD4 ER staining pattern was noted with the re-
moval of the 22 COOH-terminal pTa residues by a trun-
cation at position 243 (CD4-pTat22), although this trun-
cation resulted in a partial increase of surface CD4
expression on the corresponding BW transfectants (Fig. 8
B). In contrast, when an additional 26 amino acids (aa)
were removed, the resulting CD4–pTat48 truncated chi-
mera was expressed on the surface of BW at levels that
were as high as those expressed on BW cells transfected
with a CD4-tailless (Fig. 8 B) or a wild-type CD4 (data not
shown) construct. As this enhanced expression of surface
CD4 correlated with loss of the ER staining pattern and
appearance of fluorescence staining at the plasma mem-
brane, we concluded that a region in the pTa Cyto do-
main between aa 217 and 243 is responsible for the ob-
served ER retention function of the pTa tail. Accordingly,
the CD4–pTat48 chimera as well as the CD4-tailless pro-
tein were efficiently transported from the ER to the Golgi
apparatus, and displayed similar kinetics, as assessed by
pulse-chase metabolic labeling of COS transfectants, anti-
CD4 immunoprecipitation, and endo-H treatment. As
Figure 8. pTa tailless molecules fail to reach the plasma membrane,
but a partial truncation of the pTa Cyto tail releases a CD4–pTa chi-
meric protein from ER retention and restores cell surface expression. (A)
JR3.11 cells transfected with a bicistronic vector encoding GFP and a
pTa tailless molecule were stained with a PE-coupled anti-CD3 mAb.
Flow cytometry analysis of surface CD3 expression (shaded histogram)
was performed 48 h after transfection on electronically gated GFP1 cells.
Background values (unshaded histogram) were obtained with a PE-cou-
pled isotype-matched irrelevant mAb. (B) COS and BW cells were trans-
fected with cDNAs encoding human CD4 molecules in which the Cyto
domain has been deleted (CD4 tailless) or replaced either with a full pTa
Cyto domain (CD4-pTa) or with a truncated pTa tail lacking the
COOH-terminal 22 (CD4-pTat22) or 48 (CD4-pTat48) residues. 48 h
after transfection, COS cells were fixed, permeabilized, and stained with
an anti-CD4 mAb plus FITC-coupled goat anti–mouse Igs, and then an-
alyzed by immunofluorescence microscopy (original magnification: 363).
BW cells were stained 24 h after transfection with a Cy5-PE–coupled
anti-CD4 mAb (shaded histograms) and analyzed by flow cytometry.
Control values (unshaded histograms) were obtained with a Cy5-PE–
coupled isotype-matched irrelevant mAb.1054 An ER Retention Function for the pre–TCR-a Cytoplasmic Tail
shown in Fig. 9 A, both proteins acquired endo-H resis-
tance after a 90-min chase, and were mostly converted after
4 h. In contrast, the CD4–pTat22 chimera remained es-
sentially endo-H sensitive after 90 min and up to 50% of
pulsed chimeric protein failed to acquire endo-H resis-
tance, even after an 8-h chase.
Finally, experiments were performed to analyze the ef-
fect of equivalent truncations along the pTa protein on
pre-TCR surface expression. Bicistronic vectors containing
such pTa constructs allowed tracing of transiently trans-
fected JR3.11 cells by EGFP expression as a separate but
not as a chimeric protein. As shown in Fig. 9 B, although
the pTa deletions were not sufficient to reach TCR-a ex-
pression levels, JR3.11 cells transfected with a pTa chain
lacking the terminal 48 residues (pTat48) consistently
showed a modest increase of surface CD3 levels, compared
with CD3 expression on wild-type pTa transfectants.
Thus, as observed with the CD4–pTat48 chimera, this
particular truncation may release pTa from ER retention,
resulting in enhanced surface pre-TCR expression. In con-
trast, surface expression of a pre-TCR composed of the
pTat22 truncated protein was indistinguishable from ex-
pression levels of a wild-type pre-TCR. Collectively, our
data suggest that the observed pTa ER retention function
contributes to the regulation of surface pre-TCR expres-
sion on pre-T cells.
Discussion
Complementary approaches in this study allowed us to
conclude that differences between plasma membrane levels
of the pre-TCR and the TCR are not intrinsic to the par-
ticular cell type in which they are expressed, but depend on
the presence of a pTa chain in the former and of a TCR a
chain in the latter. We have first shown that introduction
of a conventional TCR a chain into pre-T cells increases
surface receptor expression to levels similar to those of
TCR-a/b on transfected mature T cells. Interestingly, al-
though it has been reported that expression of TCR-a pre-
cludes the formation of a TCR-b–pTa dimer in a murine
pre-T cell line (35), TCR-a transfection does not impair
endogenous pre-TCR surface expression on human pre-T
cells, indicating that TCR-b chains are in large excess and
that TCR-a and pTa are not competing each other for
pairing with TCR-b. Conversely, transfection of a TCR-
a–deficient mature T cell line with a pTa chain results in
low surface expression of the pre-TCR, relative to TCR-
a/b surface levels induced upon TCR-a transfection. Be-
cause low levels of pre-TCR expression is a common fea-
ture of both cell types, we concluded that this is an intrinsic
property of the pre-TCR complex, and therefore, the pTa
chain itself might play a direct role in controlling pre-TCR
expression levels.
In an effort to identify the structural domain/s of pTa
responsible for such a role, we took advantage of the simi-
larities and differences between the EC, TM, and Cyto do-
mains of pTa and TCR-a and produced TCR-a–pTa
chimeric proteins that were analyzed for their ability to
bring a CD3-associated chimeric TCR complex to the cell
surface. We initially focused on the EC pTa region, which
lacks a covalently associated Ig-like V domain (25), and
asked the question of whether replacement of the pTa EC
domain with the EC region of TCR-a could provide a
symmetrical shape to the TCR-b–pTa heterodimer that
could result in an increased expression at the cell surface.
Unexpectedly, however, such chimeric TCR-a–pTa
chains (aII) did not affect the levels of expression of the
pre-TCR, indicating that low surface pre-TCR expression
is not dependent on the pTa EC domain. From these data
one could infer that the lack in pTa of a partner domain
capable of pairing with the hydrophobic surface of the Vb
domain (36) does not impair expression of the complex at
the cell surface. Alternatively, the pre-TCR, by analogy
with the pre-BCR, may contain an additional not yet
identified VpreT component that fulfils that function, and
that might thus be rate limiting for proper assembly and
Figure 9. Truncation of the COOH-terminal 48 aa of the pTa Cyto
domain restores transport out of the ER of a CD4–pTa chimeric protein
and correlates with enhanced expression of the pre-TCR (A) COS cells
transfected with the CD4 tailless, CD4-pTat48, or CD4-pTat22 con-
structs described in the legend to Fig. 8 were pulse-chased labeled and lysed
as described in the legend to Fig. 6. Anti-CD4 immunoprecipitates were
treated with endo-H (1) or left untreated (2) and resolved by 12% SDS-
PAGE under reducing conditions. (B) CD3 surface expression was ana-
lyzed by flow cytometry, as described in the legend to Fig. 8 A, on JR3.11
cells transiently transfected with bicistronic vectors encoding GFP and ei-
ther the wild-type pTa (shaded histogram) or a truncated pTa lacking the
COOH-terminal 48 residues (pTat48; bold line), or a wild-type TCR-a
(thin line). Background values (dotted line) were obtained with a PE-cou-
pled isotype-matched irrelevant mAb. The positions of the mature (m) and
immature (im) proteins is indicated on the right.1055 Carrasco et al.
transport of the TCR-b–pTa heterodimer to the cell sur-
face (2, 6). Expression of such a putative VpreT is expected
to be developmentally regulated, such that its absence
would account for the impaired surface pre-TCR expres-
sion described in murine mature T cells (6). However, hu-
man mature T cells proved to be as efficient as pre-T cells
in expressing a functional TCR-b–pTa heterodimer on
their surface (this study and unpublished results), thus sup-
porting the alternative hypothesis that the pTa chain is suf-
ficient to promote surface expression of the pre-TCR
complex in the absence of an additional component.
The finding that the chimeric chain in which the pTa
EC domain was replaced with the EC TCR-a domain be-
haves as a wild-type pTa chain in terms of surface receptor
expression was not obvious, because the TCR-a C domain
displays little homology with the equivalent pTa domain
(9, 25). However, as the TCR-a C domain residues in-
volved in polar interactions with the TCR-b C domain are
all conserved in the pTa C domain, it has been proposed
that association between pTa and TCR-b C domains may
occur in a way similar to that observed in the TCR CaCb
module (3, 37). These data are against an essential function
of TCR-b–pTa assembly in controlling surface expression
levels of the pre-TCR, and suggest that the CD3/z sub-
units associated with the TCR-b–pTa heterodimer proba-
bly account for such a regulatory function. Of them, the z
chain would merely be a dispensable amplification module
for the pre-TCR, which increases its assembly rate and sta-
bility (19–22, 24), and CD3d seems dispensable for pre-
TCR assembly and function (8, 13, 38). In contrast, the
CD3ge pair, which may associate with the pre-TCR EC
domain module in a manner similar to that suggested for its
association with the TCR-a/b (39), has proved mandatory
for proper assembly of a functional pre-TCR (8, 40–42).
Therefore, it is not surprising that the wild-type pTa chain
and the chimeric chains containing both the EC and TM
domains, or exclusively the EC domain of TCR-a, are
equally capable of mediating association with CD3g,
CD3d, and CD3e subunits. What is more surprising is that
all the wild-type pre-TCR and the chimeric TCR com-
plexes are equally found physically associated with the z
chain, given that the weak association of the z chain with
the pre-TCR has recently been shown to map to the con-
necting peptide (CP) of pTa lying between its TM and Ig-
like EC domains (43). Therefore, one would expect that
the presence of the TCR-a CP domain in both chimeras
would confer an increased stability to their corresponding
receptors that might result in higher levels of surface ex-
pression. In contrast, their expression levels were as low as
those of the wild-type pre-TCR. Taken together, our re-
sults allowed us to conclude that qualitative differences in
the contribution of the CD3/z components to pre-TCR
or TCR assembly do not influence surface receptor expres-
sion levels.
A striking finding was that replacing the Cyto domain of
TCR-a with the equivalent pTa domain is sufficient for
inducing low surface expression of the chimeric TCR. It is
thus obvious that the pTa Cyto tail is directly responsible
for low surface pre-TCR expression. A strong argument in
favor of the attractive possibility that the pTa Cyto tail
functions as an ER retention signal was the observation
that individual plasma membrane proteins are mostly re-
tained in the ER and fail to reach the Golgi compartment
when appended to the pTa tail. Accordingly, pTa chains
are primarily found in internal structures which colocalize
with the ER. The demonstration that truncation of the ter-
minal 48 aa of pTa (and particularly deletion of the region
between residues 217 and 243) releases CD4–pTa chi-
meric proteins from ER retention lends further support to
that notion, and suggests that pTa ER retention determi-
nants localize primarily in the deleted region. However,
the pTa tail sequence from position 217 to 243 does not
harbor the consensus dilysine cytoplasmic motif for ER re-
tention of TM proteins (34) or the reported CD3e ER re-
tention sequence (44), suggesting the existence of alterna-
tive ER retention signals. An extensive series of point
mutations will have to be introduced into that particular
pTa sequence to unravel the precise requirements for its
retention in the ER.
As proposed for the mature TCR-a/b (45), ER reten-
tion of individual subunits or partial complexes might be an
essential mechanism for regulating assembly and levels of
expression of the pre-TCR. However, additional structural
information may be contained in the pTa Cyto tail that is
essential for surface expression of the pre-TCR, as pTa
tailless molecules fail to bring a CD3-associated pre-TCR
complex to the cell surface. Therefore, efficient surface ex-
pression of the pre-TCR complex may be the result of a
balance between complex mechanisms controlling reten-
tion and assembly of its individual components. This may
explain the finding that release of individual chimeras bear-
ing a truncated pTa tail from ER retention correlates with
recovery of wild-type protein expression levels, whereas
pTa molecules with identical truncations were unable to
recover TCR-a/b surface levels, although they were more
efficient than wild-type pTa in bringing the pre-TCR to
the cell surface. Interestingly, an ER retention mechanism
has also been proposed to account for the low plasma
membrane expression of the pre-BCR (17), although in
that case ER retention seems to be inherent to pre-B cells.
Despite the striking functional similarities between the pre-
TCR and the pre-BCR, the particular structural features of
their individual components (i.e., pTa and l5) may explain
such a discrepancy.
Finally, although one would expect that a retention
mechanism similar to that proposed here for the human
pre-TCR would be functional also in mice, the poor con-
servation of the Cyto tail in both species (6, 25) would
make this possibility unlikely. However, conserved resi-
dues in the cytoplasmic domain have been identified (25).
In addition, two independent findings strengthen our
view: first, DN thymocytes from pTa2/2 mice made
transgenic for a pTa tailless chain display increased
TCR-b surface levels, compared with DN thymocytes
from wild-type or pTa2/2 nontransgenic mice (46), and
second, low CD3 expression is common to DP thy-1056 An ER Retention Function for the pre–TCR-a Cytoplasmic Tail
mocytes from recombination activating gene (Rag)12/2
mice expressing a transgenic functional pre-TCR consist-
ing of truncated TCR-b and pTa forms that keep their
TM and Cyto regions (14). In conclusion, our data pro-
vide evidence that the pTa Cyto tail displays a novel ER
retention function which may participate in the regulation
of surface pre-TCR expression levels on pre-T cells.
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